Jacobs Jeffrey W
Known title: Chief Scientific OfficerCIK: 0001611193
Associated companies
Transaction History
| ARDX | ▼ Sell | Open Market | 5,000 | $5K | 11/22/2021 | View on chart |
| ARDX | ▼ Sell | Open Market | 754 | $748 | 11/22/2021 | View on chart |
| ARDX | ▼ Sell | Open Market | 5,000 | $6K | 11/15/2021 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,166 | $3K | 11/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Ardelyx shares IBSRELA real-world data at ACG 2026
Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.
Ardelyx shares IBSRELA real-world data at ACG 2026. Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.